ICH Abbreviations - and definitions Flashcards
ADR
(Adverse Drug Reaction ) a reaction from a treatment/ intervention where there is evidence of direct causal relationship between the reaction and the drug.
AE
Adverse event - an untoward event/ reaction that occurred during participation in the trial, whether directly related or not.
ALT
Alanine aminotransferase
-assess liver damage
AST
Asparate aminotransferase (enzyme released when liver is damaged)
-assess liver damage
BP
Blood pressure - mm Hg. The top number (systolic) is the pressure of the blood flow when your heart muscle contracts, pumping blood. The bottom number (diastolic) is the pressure measured between heartbeats.
BUN
Blood Urea Nitrogen
-used to measure kidney function
CK
Creatine Kinase - found in heart, brain, skeletal muscle, and other tissue.
-Measures muscle damage.
DCF
Data Clarification Form
GCP
GLP
GMP
- good clinical practices
- good laboratory practices
- good manufacturing practices
hCG
human chorionic gonadotropin - tested in urine for pregnancy or birth defects, uterine/ testicle cancer
ICH
International Conference Harmonization
LAR
Legally Acceptable Representative
MOA
Monoamine Oxidase - detects deficiency, mostly males. mild intellectual disability and behavioral problems beginning in early childhood - Autism/ ADHD
PK
Pharmacokinetics - refers to the movement of drug into, through, and out of the body—the time course of its absorption, bioavailability, distribution, metabolism, and excretion.
*what the body does to the drug
QA /QC
Quality Assurance / Quality Control
SUSAR
Suspected Unexpected Serious Adverse Reaction - untoward and unintended response to a study drug, which is not listed is the applicable product information, and meets one of the following serious criteria: death, life threatening, prolonged hospitalization, persistent disability, congenital anomaly or birth defect
Bias (Statistical & Operational)
The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the ESTIMATE OF A TREATMENT EFFECT DEVIATE FROM ITS TRUE VALUE
- Bias introduced through deviations in conduct is referred to as ‘operational’ bias.
- Flaw in the experiment design or data collection process ‘statistical’. examples are sampling, treatment assignment, etc
Blind Review
The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalizing the planned analysis.
Content Validity
The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.
Generalization
The extent to which the findings of a clinical trial can be reliably extrapolated from a study to a broader patient population and clinical settings
Double-Dummy
A technique for retaining the blind when administering supplies in a clinical trial, when the two treatments cannot be made identical.
Dropout
A subject in a clinical trial who for any reason fails to continue in the trial until the last visit required of him/her by the study protocol.
Full Analysis Set
The set of subjects that is as close as possible to the ideal implied by the intention-to-treat principle.
(DMC) (Data and Safety Monitoring Board, Monitoring Committee, Data Monitoring Committee)
An independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial.
Intention-To-Treat Principle
The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given
Interim Analysis
Any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to the formal completion of a trial
Meta-Analysis
The formal evaluation of the quantitative (data expressed by a number) evidence from two or more trials bearing on the same question
*statistical combination of the results of multiple studies addressing a similar research question
Multicentre Trial
A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator
Safety & Tolerability
1) Safety of a medical product concerns the MEDICAL RISK TO THE SUBJECT (assessed by medical tests, vitals, AEs, ECGs, etc
2) Tolerability of the medical product represents the DEGREE TO WHICH OVERT ADVERSE EFFECTS CAN BE TOLERATED BY THE SUBJECTS
Per Protocol Set
The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment
Statistical Analysis Plan
a document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.
Treatment Effect
An effect attributed to a treatment in a clinical trial. In most clinical trials the treatment effect of interest is a comparison (or contrast) of two or more treatments.
Treatment Emergent
An event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.
Adverse Drug Reaction (ADR)
all noxious and unintended responses to a medicinal product related to any dose that has a least a reasonable possibility of being related to the drug
Adverse Event (AE)
any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment
Applicable Regulatory Requirements
any law/regulations addressing conduct of clinical trials and IP
IRB Approval
affirmative decision of the IRB that the trial has been reviewed and may be conducted at the site within the constraints set forth by the IRB, institution, GCP, and regulatory requirements
Audit
systematic and independent exam (usually by sponsor or institution) of trial related activities and documents to determine if trial activities were conducted, data collected/analyzed, and accurately reported according to protocol, SOPs, GCP, and regulatory requirements
Audit Trail
documentation that allows reconstruction of course of events
Blinding/Masking
procedure in which one or more parties to the trial are kept unaware of treatment assignment